Beur schreef op 27 februari 2017 17:47:
Valeant beefs up salesforce, 250 reps and managers hired in three monthsFeb. 27, 2017
With the aim of driving sales of Xifaxan (rifaximin) and RELISTOR (methylnaltrexone), Valeant Pharmaceuticals (NYSE:VRX) has increased its salesforce by 40% over the past three months by hiring 250 reps and managers.
The salesforce will be dedicated to primary care physicians, the primary prescribers of Xifaxan and RELISTOR.
Salix Pharmaceuticals SVP and GM Mark McKenna says, "This will complement our existing primary care team and will allow us to capture nearly 75% of the primary care market opportunity."
Valeant says it has also expanded its pain salesforce and has established a nurse educator team to educate clinical staff in leading institutions.
===========================================
Blijft de vraag waarom Valeant dit opkrikken van de sales force niet deed voor Ruc.